IL128850A - Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture - Google Patents

Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Info

Publication number
IL128850A
IL128850A IL12885097A IL12885097A IL128850A IL 128850 A IL128850 A IL 128850A IL 12885097 A IL12885097 A IL 12885097A IL 12885097 A IL12885097 A IL 12885097A IL 128850 A IL128850 A IL 128850A
Authority
IL
Israel
Prior art keywords
cyclobutyl
chlorophenyl
unsubstituted
humans
substituted
Prior art date
Application number
IL12885097A
Other languages
English (en)
Other versions
IL128850A0 (en
Original Assignee
Abott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abott Gmbh & Co Kg filed Critical Abott Gmbh & Co Kg
Publication of IL128850A0 publication Critical patent/IL128850A0/xx
Publication of IL128850A publication Critical patent/IL128850A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
IL12885097A 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture IL128850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
IL128850A0 IL128850A0 (en) 2000-01-31
IL128850A true IL128850A (en) 2003-07-31

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885097A IL128850A (en) 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Country Status (26)

Country Link
US (3) US6174925B1 (no)
EP (1) EP0927028A1 (no)
JP (1) JP2001503737A (no)
KR (1) KR20000048501A (no)
CN (1) CN1237905A (no)
AU (1) AU724488B2 (no)
BG (1) BG64473B1 (no)
BR (1) BR9711517A (no)
CA (1) CA2266401C (no)
CZ (1) CZ93699A3 (no)
GB (1) GB9619757D0 (no)
HR (1) HRP970505A2 (no)
HU (1) HUP9904026A3 (no)
ID (1) ID18320A (no)
IL (1) IL128850A (no)
MY (1) MY116150A (no)
NO (1) NO991358L (no)
NZ (1) NZ334580A (no)
PL (1) PL332305A1 (no)
RU (1) RU2245709C2 (no)
SK (1) SK31999A3 (no)
TR (1) TR199900618T2 (no)
TW (1) TW580385B (no)
UA (1) UA64726C2 (no)
WO (1) WO1998011884A1 (no)
ZA (1) ZA978450B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
AR019727A1 (es) * 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CN1230162C (zh) * 1998-11-12 2005-12-07 史密丝克莱恩比彻姆有限公司 改进释放胰岛素致敏剂和另一抗糖尿病药的药用组合物
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
EP1185232A1 (en) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
CA2501321C (en) * 2002-10-05 2008-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
WO2005041962A1 (en) * 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
CN101394847B (zh) * 2006-01-06 2017-05-24 塞普拉柯公司 作为单胺重摄取抑制剂的环烷基胺类
AU2007296074B2 (en) 2006-09-15 2012-07-12 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
CN101528265A (zh) * 2006-11-22 2009-09-09 Sk化学株式会社 西布曲明和β-环糊精的包络物
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
SG11201403165SA (en) 2011-12-30 2014-08-28 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
GB9619757D0 (en) 1996-11-06
TR199900618T2 (xx) 1999-06-21
MY116150A (en) 2003-11-28
PL332305A1 (en) 1999-08-30
NO991358D0 (no) 1999-03-19
BG103277A (en) 2000-01-31
HUP9904026A3 (en) 2000-07-28
SK31999A3 (en) 1999-12-10
US6617360B1 (en) 2003-09-09
ID18320A (id) 1998-03-26
CA2266401C (en) 2007-01-30
CA2266401A1 (en) 1998-03-26
NZ334580A (en) 2000-09-29
RU2245709C2 (ru) 2005-02-10
KR20000048501A (ko) 2000-07-25
ZA978450B (en) 1999-03-19
IL128850A0 (en) 2000-01-31
CZ93699A3 (cs) 1999-08-11
HUP9904026A2 (hu) 2000-05-28
US20040077730A1 (en) 2004-04-22
US6174925B1 (en) 2001-01-16
TW580385B (en) 2004-03-21
NO991358L (no) 1999-03-19
JP2001503737A (ja) 2001-03-21
WO1998011884A1 (en) 1998-03-26
AU4774097A (en) 1998-04-14
HRP970505A2 (en) 1998-08-31
EP0927028A1 (en) 1999-07-07
BR9711517A (pt) 1999-08-24
CN1237905A (zh) 1999-12-08
BG64473B1 (bg) 2005-04-30
AU724488B2 (en) 2000-09-21
UA64726C2 (uk) 2004-03-15

Similar Documents

Publication Publication Date Title
IL128850A (en) Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture
HUP0004300A3 (en) Pharmaceutical composition comprising (s)-n-ethyl-3-[1-(dimethylamino)ethyl]-n-methyl-phenyl-carbamate and an antioxidant
HUP0200709A3 (en) Triazole compounds with dopamine-d3-receptor affinity, pharmaceutical compositions containing them and their use
AU3622599A (en) Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
HUP0100064A3 (en) Synergetic fungicidal combination comprising amides derivative and chlorothalonil and its use
PL313769A1 (en) Azole derivative and pharmaceutical composition thereof
HUP0202648A3 (en) Imidazolyl derivatives, pharmaceutical compositions containing them and their use
HUP0000145A2 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ZA947710B (en) Imidazol-4 ylpiperdine derivatives, their preparation and their application in therapeutics.
HUP0100717A3 (en) Synergetic fungicidal composition comprising amide compound and its use
HUP0003063A3 (en) Synergetic fungicidal composition and its use
HUP0002361A3 (en) Synergetic fungicidal composition, based on halogenbenzimidazol derivative, manufacture and use thereof
IL118644A0 (en) N-Ú(1,4-diazabicyclo Ú2.2.2¾ oct-2-yl) methyl¾ benzamide derivatives their preparation and their application in therapeutics
HK1048917A1 (zh) 含有n-丙酮基苯甲酰胺和滅菌丹的殺真菌組合物
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
AU5922094A (en) 3-quinolyl-substituted dihydropyridines, processes for theirpreparation and their use in medicaments
EP0654479A3 (en) Esculetin derivatives, process for their preparation and their use as pharmaceutical compositions.
HUP0002975A3 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate and pharmaceutical composition containing it
HUP0104623A3 (en) Cyclosporin solution, pharmaceutical composition comprising thereof and its use
HK1041689A1 (en) ((Aminoiminomethyl)amino) alkanecarboxamides and their applications in therapy.
HUP0004838A3 (en) Synergetic fungicidal combination comprising benzyl-ether derivative and n-acetonyl-benzamide derivative and its use
AU1255900A (en) Pharmaceutical composition comprising bupropion hydrochloride
ZA942884B (en) 2-amino-4-heteroaryl-1. 4-dihydropyridines processes for their preparation and their use in medicaments

Legal Events

Date Code Title Description
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees